Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein

Eiichi Fuse, Hiromi Tanii, Noriaki Kurata, Hiroyuki Kobayashi, Yasuhiro Shimada, Tomohide Tamura, Yasutsuna Sasaki, Yusuke Tanigawara, Richard D. Lush, Donna Headlee, William D. Figg, Susan G. Arbuck, Adrian M. Senderowicz, Edward A. Sausville, Shiro Akinaga, Takashi Kuwabara*, Satoshi Kobayashi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

208 Scopus citations

Abstract

The pharmacokinetics of UCN-01 after administration as a 72- or 3-h infusion to cancer patients in initial Phase I trials displayed distinctive features that could not have been predicted from preclinical data. The distribution volumes (0.0796-0.158 liters/kg) and the systemic clearance (0.0407-0.252 ml/h/kg) were extremely low, in contrast to large distribution volume and rapid systemic clearance in experimental animals. The elimination half-lives (253-1660 h) were unusually long. In vitro protein binding experiments demonstrated that UCN-01 was strongly bound to human α1-acid glycoprotein. The results suggest that unusual pharmacokinetics of UCN-01 in humans could be due, at least in part, to its specifically high binding to α1-acid glycoprotein.

Original languageEnglish
Pages (from-to)3248-3253
Number of pages6
JournalCancer Research
Volume58
Issue number15
StatePublished - 1 Aug 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein'. Together they form a unique fingerprint.

Cite this